Drug Trial Radar · NCT02503332
Study of Pegcetacoplan (APL-2) Therapy in Patients With Geographic Atrophy
Last checked: Nov 20, 2026Latest source record: Oct 6, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
246
Actual
Start
Sep 24, 2015
Primary completion
Jul 14, 2017
Study completion Jan 17, 2018
Sponsor
- Lead sponsor
- Apellis Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 20, 2015
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Single group
- Masking
- Single (participant)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objectives of the study are to assess the safety, tolerability and evidence of activity of multiple intravitreal (IVT) injections of pegcetacoplan in subjects with Geographic Atrophy associated with Age-Related Macular Degeneration (AMD).
Conditions
- Geographic Atrophy
Interventions
PegcetacoplanDrug
Sham ProcedureOther
Primary outcomes
What the sponsor says the trial is designed to measure.
- Least Square (LS) Mean Change From Baseline in Square Root GA Lesion Size in the Study Eye at Month 12Time frame: Baseline (screening) and Month 12.
- Number of Subjects With Treatment Emergent Adverse Events (TEAEs) in the Study Eye, Including by SeverityTime frame: From the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
Locations
46 sites in 3 countries. Site status is shown where the registry gives one.
Retina Speciality Institute
Mobile, Alabama
Retinal Research Institute
Phoenix, Arizona
Retina Vitreous Asociates Mdical Goup
Beverly Hills, California
The Gavin Herbert Eye Institute/UC Irvine
Irvine, California
University of Southern California - USC Eye Institute
Los Angeles, California
Byers Eye Institute at Stanford, Stanford School of Medicine
Palo Alto, California
New England Retina Associates
New London, Connecticut
Florida Eye Microsurgical Institute, Inc.
Boynton Beach, Florida
Retina Health Center
Fort Myers, Florida
Bascom Palmer Eye Institute
Miami, Florida
South East Retina
Augusta, Georgia
Illinois Retina Associates
Harvey, Illinois
Midwest Eye Institute
Indianapolis, Indiana
Elman Research
Baltimore, Maryland
Ophthalmic Consultants of Boston
Boston, Massachusetts
Associated Retinal Consultants PC
Grand Rapids, Michigan
Associated Retinal Consultants, PC
Traverse City, Michigan
Mayo Clinic
Rochester, Minnesota
Eyesight Opthalmic Services PA
Portsmouth, New Hampshire
Vitreous Retina Macula Consultants of New York
New York, New York
Charlotte Eye Ear Nose and Throat Associates
Charlotte, North Carolina
Duke University, Duke Eye Center
Durham, North Carolina
Charlotte Eye Ear Nose and Throat Associates
Statesville, North Carolina
Cleveland Clinic Foundation/ Cole Eye Institute
Cleveland, Ohio
Retina Associates of Cleveland
Cleveland, Ohio
Mid Atlantic
Philadelphia, Pennsylvania
Black Hills Regional Eye Institute
Rapid City, South Dakota
Tennessee Retina, PC
Nashville, Tennessee
Retina Research Institute of Texas
Abilene, Texas
Retina Research Center
Austin, Texas
Retina Consultants of Houston
Houston, Texas
Valley Retina Institute, PA
McAllen, Texas
Retina Specialists
Plano, Texas
Retina Consultants of Houston (The Woodlands)
The Woodlands, Texas
University of Utah
Salt Lake City, Utah
Marsden Eye Specialists
Parramatta, New South Wales, Australia
Save Sight Institute, Sydney Eye Hospital
Sydney, New South Wales, Australia
Sydney Retina Clinic and Day Surgery
Sydney, New South Wales, Australia
Sydney West Retina
Westmead, New South Wales, Australia
Hobart eye Surgeons
Hobart, Tasmania, Australia
Showing 40 of 46 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.